SCHEDULE: Blue Owl Capital Boosts Larimar Therapeutics Stake

Blue Owl Capital Holdings LP has increased its beneficial ownership in Larimar Therapeutics, Inc. to 9.99% of common stock.

Summary

• Blue Owl Capital Holdings LP filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Larimar Therapeutics, Inc.
• The reporting person, Blue Owl Capital Holdings LP, beneficially owns 8,464,663 shares of Larimar Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the total class of Common Stock.
• The reported securities consist of 6,823,690 shares of Common Stock and 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock.
• The percentage of class is calculated based on 85,590,392 shares of Common Stock outstanding as of November 3, 2025, adjusted for a decrease of 2,500,000 shares exchanged for Series A Convertible Preferred Stock and an increase of 1,640,973 shares from Series A Preferred Stock conversion.
• A conversion blocker limits the holder's beneficial ownership to 9.9%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive as a significant institutional investor maintains a substantial stake, potentially signaling confidence in Larimar Therapeutics, though it's a routine disclosure of ownership rather than new operational news.

Positives

• A significant institutional investor, Blue Owl Capital Holdings LP, maintains a substantial stake in Larimar Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The inclusion of convertible preferred stock in the holding structure suggests a strategic, long-term investment approach.

Future Outlook

The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Larimar Therapeutics or Blue Owl Capital regarding future performance or strategy.

Management Comments

• Karen Hager, Chief Compliance Officer of Blue Owl Capital Holdings LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors holding more than 5% but less than 20% of a company's stock, indicating a significant, but non-activist, stake. This particular filing shows a continued or increased interest from Blue Owl Capital in the biotechnology sector, specifically in Larimar Therapeutics.

Stakeholder Impact

• Shareholders: May view the continued significant stake by Blue Owl Capital as a positive signal of institutional confidence in Larimar Therapeutics.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by Blue Owl Capital Holdings LP in Larimar Therapeutics. While this suggests institutional confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It's a disclosure of an existing, albeit adjusted, ownership position. Therefore, a 'hold' recommendation is appropriate, pending further operational updates from Larimar Therapeutics.

Keywords

Larimar Therapeutics, Blue Owl Capital, Schedule 13G, Beneficial Ownership, Common Stock, Series A Preferred Stock, Institutional Investor, Equity Stake, SEC Filing